Crinetics Pharmaceuticals (CRNX) Competitors $37.35 +0.87 (+2.38%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CRNX vs. VTRS, ITCI, SMMT, MRNA, RDY, CTLT, SRPT, QGEN, PCVX, and ASNDShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Viatris (VTRS), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Viatris Intra-Cellular Therapies Summit Therapeutics Moderna Dr. Reddy's Laboratories Catalent Sarepta Therapeutics Qiagen Vaxcyte Ascendis Pharma A/S Crinetics Pharmaceuticals (NASDAQ:CRNX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability. Which has more risk & volatility, CRNX or VTRS? Crinetics Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Does the MarketBeat Community favor CRNX or VTRS? Crinetics Pharmaceuticals received 134 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 69.33% of users gave Crinetics Pharmaceuticals an outperform vote while only 35.48% of users gave Viatris an outperform vote. CompanyUnderperformOutperformCrinetics PharmaceuticalsOutperform Votes15669.33% Underperform Votes6930.67% ViatrisOutperform Votes2235.48% Underperform Votes4064.52% Is CRNX or VTRS more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -36.12% -31.89% Viatris -5.87%16.46%7.09% Which has higher valuation & earnings, CRNX or VTRS? Viatris has higher revenue and earnings than Crinetics Pharmaceuticals. Viatris is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M3,333.75-$214.53M-$3.73-10.01Viatris$15.05B0.90$54.70M-$0.74-15.27 Does the media favor CRNX or VTRS? In the previous week, Crinetics Pharmaceuticals had 7 more articles in the media than Viatris. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 5 mentions for Viatris. Viatris' average media sentiment score of 0.66 beat Crinetics Pharmaceuticals' score of 0.50 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CRNX or VTRS? 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend CRNX or VTRS? Crinetics Pharmaceuticals presently has a consensus target price of $74.40, indicating a potential upside of 99.20%. Viatris has a consensus target price of $13.67, indicating a potential upside of 20.94%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Crinetics Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Viatris 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryCrinetics Pharmaceuticals beats Viatris on 11 of the 18 factors compared between the two stocks. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.46B$6.58B$5.35B$9.06BDividend YieldN/A2.95%5.13%4.02%P/E Ratio-10.019.8389.4817.34Price / Sales3,333.75306.911,251.39134.53Price / CashN/A61.4443.7535.97Price / Book4.636.055.324.80Net Income-$214.53M$154.62M$122.60M$224.91M7 Day Performance-7.98%-1.70%0.88%1.90%1 Month Performance-28.30%2.75%4.81%5.08%1 Year Performance3.18%2.60%27.90%21.15% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.72 of 5 stars$37.35+2.4%$74.40+99.2%+1.5%$3.46B$1.04M-10.01210Short Interest ↑VTRSViatris2.2015 of 5 stars$11.75+0.7%$13.67+16.3%-1.4%$14.02B$15.05B-15.8837,000Short Interest ↑ITCIIntra-Cellular Therapies3.8 of 5 stars$127.26+34.1%$97.23-23.6%+91.4%$13.49B$612.78M-146.27560Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics2.8456 of 5 stars$18.02+1.0%$33.57+86.3%+468.1%$13.29B$700,000.00-64.35105MRNAModerna4.7373 of 5 stars$34.19-19.1%$78.83+130.6%-66.1%$13.16B$5.06B-5.875,600Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageHigh Trading VolumeRDYDr. Reddy's Laboratories2.0189 of 5 stars$15.28-0.9%$17.00+11.3%+10.6%$12.75B$3.35B24.4127,048News CoverageCTLTCatalent1.2524 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.42B-28.0916,900News CoverageSRPTSarepta Therapeutics4.9442 of 5 stars$117.14-6.1%$178.71+52.6%+0.8%$11.19B$1.64B93.711,314Analyst ForecastAnalyst RevisionNews CoverageQGENQiagen4.0945 of 5 stars$45.97+2.9%$51.50+12.0%-0.2%$10.49B$1.97B117.875,967Short Interest ↓News CoveragePCVXVaxcyte1.9897 of 5 stars$80.53-0.7%$145.71+80.9%+35.7%$10.04BN/A-17.51160Insider TradeAnalyst RevisionNews CoverageASNDAscendis Pharma A/S3.6193 of 5 stars$131.74+2.0%$192.07+45.8%-3.2%$8.00B$327.43M-16.30640Short Interest ↓ Related Companies and Tools Related Companies Viatris Competitors Intra-Cellular Therapies Competitors Summit Therapeutics Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Catalent Competitors Sarepta Therapeutics Competitors Qiagen Competitors Vaxcyte Competitors Ascendis Pharma A/S Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRNX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
